In persons with diabetes, we are concerned about cardiovascular (heart) disease and seek to prevent it. GLP-1 receptor agonists and SGLT-2 inhibitors are two drug classes that have proven their benefit in persons with type 2 diabetes with or without heart disease. It is worth noting that some drugs within each of these classes work better than others when it comes to preventing primary and secondary heart related events. Within the SGLT-2 inhibitor drug class, canagliflozin and empagliflozin have proven their heart related benefits. Well now, dapagliflozin is proving its benefit for persons with type 2 diabetes with cardiovascular (heart) disease. Just this week, results from phrase III trial (DAPA-HF) revealed dapagliflozin decreased risk of cardiovascular (heart related) death and decreased worsening of heart failure in persons with heart failure with reduced ejection faction with or without diabetes. If you want more details on this trial, please click below.
Please share your thoughts and subscribe to receive my blogs.
#heart #failure #cardiovascular #death #reduction #dapagliflozin
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.